Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma

[1]  F. Russo,et al.  Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as First-Line Treatment In High-Risk Peripheral T-Cell/NK Lymphomas: A Phase II Trial. , 2010 .

[2]  S. Pileri,et al.  Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  B. Martínez-Delgado,et al.  Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. , 2009, Critical reviews in oncology/hematology.

[4]  D. Weisenburger,et al.  International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Shinton.  WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues , 2007 .

[6]  A. Horwich,et al.  Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. , 2007, Haematologica.

[7]  A. Zelenetz,et al.  Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma , 2006, British journal of haematology.

[8]  Y. Bang,et al.  First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy ± radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma , 2006, Leukemia & lymphoma.

[9]  S. Pileri,et al.  Gemcitabine as frontline treatment for cutaneous T‐cell lymphoma , 2005, Cancer.

[10]  K. Ding,et al.  Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma , 2004, Cancer.

[11]  B. Hennessy,et al.  Non-Hodgkin lymphoma: an update. , 2004, The Lancet. Oncology.

[12]  C. Dearden,et al.  Peripheral T-cell lymphomas: diagnosis and management , 2003 .

[13]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[14]  O. Hermine,et al.  Treatment of Adult T-cell Leukemia-Lymphoma by CHOP Followed by Therapy with Antinucleosides, Alpha Interferon and Oral Etoposide , 2002, Leukemia & lymphoma.

[15]  V. Diehl,et al.  T-cell Non-Hodgkin's Lymphoma in Adults: Clinicopathological Characteristics, Response to Treatment and Prognostic Factors , 2002, Leukemia & lymphoma.

[16]  I. Bodrogi,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Pileri,et al.  Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Allerheiligen,et al.  Preclinical, pharmacologic, and phase I studies of gemcitabine. , 1997, Seminars in oncology.

[20]  W. Plunkett,et al.  Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.

[21]  G. Peters,et al.  Synergistic interaction between cisplatin and gemcitabine in vitro. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. Larsson,et al.  Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors. , 1995, Seminars in oncology.

[23]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[24]  V. Heinemann,et al.  Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. , 1988, Cancer research.

[25]  Y. Bang,et al.  Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  A. Evens,et al.  Treatment of T-cell non-hodgkin’ lymphoma , 2004, Current treatment options in oncology.

[27]  A. Avilés,et al.  Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy , 2003, Medical oncology.

[28]  A. Carrato,et al.  Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.